Findings

What do systematic reviews say?

6 questions · 6 findings · 3 reviews

Sort:Best matchNewest Highest certainty Download CSV

No studies found 0 · 0%GRADE not reported 0 · 0%Very low 1 · 16.7%Low 1 · 16.7%Moderate 2 · 33.3%High 2 · 33.3%

Anti‐IL‐5 mAb (mepolizumab) vs placebo (on top of topical steroids)

Serious adverse events · patients with severe chronic rhinosinusitis with nasal polyps

It is very uncertain whether anti‐IL‐5 mAb (mepolizumab) changes serious adverse events compared with placebo (on top of topical steroids) (very low certainty).

1 finding from 1 review

Biologics for chronic rhinosinusitis 2021 · Cochrane Headline outcomes only
RR 1.57 [0.07, 35.46]
2 studies · 135 participants
Very low

Mepolizumab 300 mg vs placebo

Serious adverse events · patients with chronic obstructive pulmonary disease

Mepolizumab 300 mg showed no clear difference in serious adverse events compared with placebo (moderate certainty).

1 finding from 1 review

Anti‐IL‐5 therapies for chronic obstructive pulmonary disease 2020 · Cochrane Headline outcomes only
Odds ratio 0.84 [0.56, 1.27]
1 study · 451 participants
Moderate

Mepolizumab 750 mg vs placebo

Serious adverse events · patients with chronic obstructive pulmonary disease

Mepolizumab 750 mg showed no clear difference in serious adverse events compared with placebo (low certainty).

1 finding from 1 review

Anti‐IL‐5 therapies for chronic obstructive pulmonary disease 2020 · Cochrane Headline outcomes only
Odds ratio 3 [0.22, 40.93]
1 study · 18 participants
Low

Mepolizumab 100 mg vs placebo

Serious adverse events · patients with chronic obstructive pulmonary disease

Mepolizumab 100 mg showed no clear difference in serious adverse events compared with placebo (moderate certainty).

1 finding from 1 review

Anti‐IL‐5 therapies for chronic obstructive pulmonary disease 2020 · Cochrane Headline outcomes only
Odds ratio 0.82 [0.65, 1.05]
2 studies · 1285 participants
Moderate

Mepolizumab intravenous (IV) vs placebo

Serious adverse events · people with asthma

Mepolizumab intravenous (IV) leads to lower serious adverse events compared with placebo (high certainty).

1 finding from 1 review

Anti‐IL‐5 therapies for asthma 2022 · Cochrane Headline outcomes only
Risk ratio 0.59 [0.37, 0.94]
3 studies · 751 participants
High

Mepolizumab subcutaneous (SC) vs placebo

Serious adverse events · people with asthma

Mepolizumab subcutaneous (SC) showed no clear difference in serious adverse events compared with placebo (high certainty).

1 finding from 1 review

Anti‐IL‐5 therapies for asthma 2022 · Cochrane Headline outcomes only
Risk ratio 0.68 [0.46, 1.01]
3 studies · 1231 participants
High